Slide 1: Corporate Presentation March 2016
Corporate Presentation March 2016
Slide 2: Safe Harbor statement
Safe Harbor statement Forward-Looking Statements This presentation contains certain statements that may be deemed to be “forward looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements
Slide 3: Our Mission: A New Vision for Colorectal Cancer Prevention
By removing barriers, changing perceptions, & increasing willingness for screening Our Mission A New Vision for Colorectal Cancer Prevention
Slide 4: About Check-Cap
Ingestible X-ray scanning capsule Tracking control and data collection unit Image processing and viewing Ongoing in Israel Plan to initiate U.S. pivotal trial in 2017 GE, Fosun Pharma, Pontifax Founded - 2005, Employees - 60 Located - Israel, Boston About Check-Cap Technology Clinical Trials $ 50mn
Slide 5: Colorectal Cancer: a major public health problem
Annual new cases world-wide - Colorectal Cancer a major public health problem Source: American Cancer Society World Health Organization J Natl Cancer Inst. 2011; 103:1-12 (Mariotto) 134k 49k 471k 228k 253k 139k 1.36m 694k Annual deaths world-wide - Second leading cause of cancer deaths in U.S. Treat
Slide 6: Colorectal Cancer: highly preventable
Cancer Precancerous phase, readily detectable by structural examinations of the colon Cancer patient Colorectal Cancer highly preventable Small Adenomatous Polyp (< 1cm) Screening can find polyps that can be removed before they turn into cancer Source: Gastro 1997;112:594-692 (Winawer) ACS recommend
Slide 7: Preventing colon cancer should be a major reason for getting tested
Preventing colon cancer should be a major reason for getting tested Source: AGA Institute Guidelines for the Early Detection of Colorectal Cancer and Adenomatous Polyps Gastroenterology 2008; 134: 1570-1595 (Levin) ACS recommendations for colorectal cancer early detection CRC screening tests cancer
Slide 8: U.S. screening rates and the national goal
U.S screening rates and the national goal Source: CDC NHIS Survey results MMWR 2015 CA Cancer J Clin 2014;64:104-17 (Seigel) Significant declines in colorectal cancer incidence have been attributed to screening ages 50-75
Slide 9: Perceptions and Barriers
Perceptions and Barriers screening colonoscopy Bowel Prep Restricted diet Sedation Pre-test fasting Fear of pain and discomfort Feeling of vulnerability Embarrassment A significant majority judged bowel preparation to be the worst part of the process, and the main barrier Patient Education and Couns
Slide 10: Removal of prep may increase screening rates
Removal of prep may increase screening rates Insertion of endoscope Laxative preparation Fasting req. Feeling Embarrassed Concern over pain Other reasons 15% 32% 21% 13% 11% 8% 86% of respondents would be much or somewhat more likely to undergo screening if laxative prep were to be removed. Source:
Slide 11: Check-Cap System
Imaging Data + Positioning Data Check-Cap System Ingestible imaging capsule Tracker/recorder - Biocompatible patch worn on patient's back 3D colon image viewer The Check-Cap System is not available for sale or clinical use in any jurisdiction.
Slide 12: Ultra-low dose X-ray scanning capsule
Ultra-low dose X-ray Patented technology detects photons from Back-scattering and Fluorescence scanning capsule XRF CMT Compton X-Ray As the capsule moves naturally, it scans the inner lining of the colon in a 360 degree arc, scanning only when in motion Patients drink a small amount of contrast age
Slide 13: Patients continue their daily routine
Patients continue their daily routine As the capsule travels naturally, it transmits scanning and location Data to the Capsule Positioning System, mapping the structures of the internal colon. The capsule is excreted naturally and the patient is notified. Capsule route in colon C apsule P ositioning
Slide 14: Physician review of clinical images
Physician review of clinical images Image for illustration only
Slide 15: Clinical data generation
Clinical data generation Preliminary Efficacy 100 patients, ongoing 2016 ü Safety ü 3D Imaging ü Polyp detection validated by colonoscopy. Clinical proof of concept 10 patients 2013 ü Safety ü Radiation Dosage ü Localization, Automated ü Scanning, Imaging 75 patients 2010 Capsule motility ü Safety ü
Slide 16: Case study: polyp in the sigmoid colon
Case study A section of the sigmoid colon where a polyp was located A 3D map of the colon as captured by the system polyp in the sigmoid colon Fillet-type processing Tube-type processing Image taken during screening colonoscopy of a 20mm polyp on a large stem in the sigmoid colon A/P view
Slide 17: Case study: polyp in the ascending colon
Case study A section of the ascending colon where a polyp was located A 3D map of the colon as captured by the system polyp in the ascending colon Fillet-type processing Tube-type processing Image taken during colonoscopy of a 4mm sessile polyp on a haustra in the ascending colon
Slide 18: Compelling market opportunity
Compelling market opportunity $ 4B annual U. S. market opportunity** Source: * - population between ages 50-84 at average risk, U.S. Census Bureau, Pop. Division, 2014, company estimates ** - For patients screened once every 5 years at average Check-Cap System price of $600 J Clin Gastroenterol 2014
Slide 19: Intellectual Property: robust portfolio
Intellectual Property robust portfolio Core patents granted in major jurisdictions 20 granted, 1 allowed, and 34 pending worldwide including the U.S. PTO, European Patent Organization, China, Japan, & India covering the core technology: • Intra-Lumen Polyp Detection - system and method for an ingest
Slide 20: Management
Bill Densel 23 years of healthcare industry experience, including CEO of Beacon Endoscopic, CEO of Dune Medical, Cytyc/Hologic, Boston Scientific, Genzyme Biosurgery. Dr. Yoav Kimchy 12 years of executive R&D experience, including Vice President of R&D at V-Target Ltd. and Director of Cardiovascular
Slide 21: Financial & Corporate summary
Financial & Corporate summary • $14.2 million cash as of December 31, 2015 • Cash runway through Q1 2017 Financial Position • US IPO: February 2015 • Traded on the NASDAQ: CHEK • Warrants traded on the NASDAQ: CHEKW • 11.9 million ordinary shares outstanding • Affiliate ownership: 22% Capital Struct
Slide 22: Target milestones
Target milestones * Capital and strategic partner dependent Design release and transfer to production Complete multi-center clinical study Preliminary Efficacy demonstration CE Mark submission U.S Pilot Trial initiation H1 16 H2 16 H1 17 U.S. Pivotal Trial initiation EU Post Market study initiation
Slide 23: Investment highlights
Investment highlights clear strategy Leading-edge technology Significant market opportunity clinically demonstrated Proof of concept and polyp detection Extensive expertise within management & advisory teams Robust IP portfolio
Slide 24: A New Vision For Colorectal Cancer Prevention
A New Vision For Colorectal Cancer Prevention